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Summary: Lenalidomide is an immunomodulatory agent that has demonstrated clinical benefit 
for patients with relapsed or refractory mantle cell lymphoma (MCL); however, despite this 
observed clinical activity, the mechanism of action (MOA) of lenalidomide has not been 
characterized in this setting. We investigated the MOA of lenalidomide in clinical samples from 
patients enrolled in the CC-5013-MCL-002 (ClinicalTrials.gov: NCT00875667) trial comparing 
single-agent lenalidomide vs investigator’s choice single-agent therapy and validated our findings 
in pre-clinical models of MCL. Our results reveal a significant increase in NK-cells relative to total 
lymphocytes in lenalidomide responders compared to non-responders that was associated with 
a trend towards prolonged progression free survival and overall survival. Clinical response to 
lenalidomide was independent of baseline tumor microenvironment expression of its molecular 
target cereblon, as well as genetic mutations reported to impact clinical response to the Bruton’s 
tyrosine kinase inhibitor ibrutinib. Preclinical experiments revealed lenalidomide enhanced NK 
cell mediated cytotoxicity against MCL cells via increased lytic immunological synapse formation 
and secretion of granzyme B. In contrast, lenalidomide exhibited minimal direct cytotoxic effects 
against MCL cells. Taken together, these data provide the first insight into the clinical activity of 
lenalidomide against MCL revealing a predominately immune mediated MOA. 
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Introduction: 
Mantle cell lymphoma (MCL) is a rare and aggressive histological subtype representing 
approximately 2% to 7%  of non-Hodgkin’s lymphoma (NHL) with a median overall survival of 
approximately 4 years (M. Dreyling, Weigert, Hiddemann, & European, 2008). While the 
introduction of high dose chemotherapy (with and without autologous stem cell transplantation) 
and the addition of the anti-CD20 monoclonal antibody rituximab to existing regimens has 
prolonged progression free survival in front line subjects, ultimately the disease remains incurable 
(Delarue et al., 2012; Gianni et al., 2003; Romaguera et al., 2005). Despite the availability of 
agents such as bortezomib, temsirolimus and ibrutinib, the median overall survival remains poor 
(less than 2 years) in patients with relapsed or refractory MCL (R/R MCL) (Martin Dreyling et al., 
2015; Wang  et al., 2013). Lenalidomide is an immunomodulatory agent that has demonstrated 
significant clinical benefit for patients with R/R MCL and is approved for patients who have 
received at least 2 prior therapies, including the proteasome inhibitor bortezomib (Goy et al., 2013; 
Habermann et al., 2009; Wiernik et al., 2008; Witzig et al., 2011; Zinzani et al., 2013). Given the 
availability of treatment options for R/R MCL and the lack of consensus regarding a standard of 
care in this setting, the phase 2 MCL-002 (SPRINT) study was designed to evaluate single-agent 
lenalidomide compared to investigator’s choice single-agent therapy including rituximab, 
gemcitabine, fludarabine, chlorambucil, or cytarabine (Trněný et al., 2016). In MCL-002, 
lenalidomide monotherapy resulted in significant improvements in progression free survival (PFS) 
[8.7 months] and rates of objective [68%], complete and unconfirmed complete response [5%] 
compared to investigator’s choice [5.2 months PFS; 9% ORR; 0% CR/Cru, respectively], 
providing the first direct comparison of lenalidomide to other treatment options for R/R MCL 
(Trněný et al., 2016).    
Lenalidomide and other IMiD® immunomodulatory agents exhibit a dual mechanism of 
action, consisting of direct cytotoxic effects against tumor cells as well as targeting the tumor 
microenvironment through immunomodulation of T and NK cell activity (Davies et al., 2001; 
Gandhi et al., 2014; Offidani et al., 2014; Schafer et al., 2003; Wu et al., 2008; Yang et al., 2012; 
L. H. Zhang et al., 2013). In NHL, the immunomodulatory effects of lenalidomide include repair of 
dysfunctional T-cell immune synapses in follicular lymphoma (FL) and chronic lymphocytic 
leukemia (CLL) (Ramsay et al., 2009; Ramsay et al., 2008). Tumor-infiltrating T cells from patients 
with FL had reduced formation of immune synapses compared to cells from healthy donors; 
however, treatment with lenalidomide reversed this by enhancing immune synapse formation. 
Lenalidomide also enhanced rituximab antibody-dependent cellular cytotoxicity (ADCC) in pre-
clinical NHL models which provided pre-clinical support for investigation of lenalidomide in 
combination with rituximab combination regimens for patients with NHL (Gribben, Fowler, & 
Morschhauser, 2015; Hernandez-Ilizaliturri, Reddy, Holkova, Ottman, & Czuczman, 2005; Reddy 
et al., 2008; Wu et al., 2008; L. Zhang et al., 2009). 
Lenalidomide directly binds Cereblon, a substrate receptor for the CRL4CRBN ubiquitin E3-
ligase complex that includes damage-specific DNA binding protein (DDB1), cullin 4A (Cul4) and 
RING finger protein 1 (ROC1) (Ito et al., 2010). Upon drug binding to Cereblon, specific substrate 
proteins are recruited to the E3 ligase and are targeted for ubiquitination and subsequent 
proteasomal degradation. The first such identified substrates, Ikaros and Aiolos, are lymphoid 
transcription factors that were found to be degraded to various extents in the presence of 
thalidomide, lenalidomide and pomalidomide in cell lines from various hematologic malignancies 
including multiple myeloma (MM), myelodysplastic syndrome (MDS), diffuse large B-cell 
lymphoma (DLBCL) and primary T cells (Gandhi et al., 2014; Gribben et al., 2015; Hagner et al., 
2015; Kronke et al., 2015; Kronke et al., 2014; G. Lu et al., 2014). In MM cells treated with 
lenalidomide or pomalidomide, Aiolos and Ikaros degradation resulted in direct cell-autonomous 
effects including decreased proliferation which is associated with decreased levels of c-myc and 
interferon regulatory factor 4 (IRF4) (Bjorklund et al., 2015; Gang Lu et al., 2014). Lenalidomide 
treatment of T and NK cells resulted in increased interleukin-2 (IL-2) and interferon-gamma (IFN-
γ) secretion leading to enhanced immune mediated cytotoxicity including enhanced ADCC 
(Davies et al., 2001; Gandhi et al., 2014; Ramsay et al., 2008; Wu et al., 2008). Furthermore, 
Aiolos-deficient NK cells were shown to be strongly hyper-reactive in multiple tumor models 
(Holmes et al., 2014).  
Despite the demonstrated clinical benefits of lenalidomide in R/R MCL and advances into 
the molecular mechanism in specific lymphoid malignancies, the MOA in MCL has remained 
largely uncharacterized. Here, we report that patients responding to lenalidomide therapy, but not 
non-responders, experienced significant increases in CD56+ NK cells relative to total lymphocytes 
which was associated with a trend towards prolonged progression free survival and overall 
survival. Preclinical experiments reveal lenalidomide increased NK cell mediated cytotoxicity 
against MCL cell lines, primarily through enhanced formation of lytic NK cell immunological 
synapses and granzyme B secretion; compared to a lack in direct anti-proliferative effects against 
MCL cell lines. These data are consistent with a primarily immune-mediated mechanism of 
lenalidomide clinical activity in MCL. 
 
Materials and Methods: 
MCL Cell Culture 
Mantle Cell Lymphoma (Jeko-1, JVM-2, Mino, Rec1, Granta-519, Z138) were obtained from 
American Type Culture Collection (ATCC) and were cultured in RPMI-1640 containing 10-20% 
fetal bovine serum, 1% Penicillin/Streptomycin, 2 mM L-glutamine, and 1 mM sodium pyruvate.  
 
Immunoblotting 
Cells were lysed in RIPA buffer containing 20 mM Tris, pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% 
Nonidet P-40, 10% glycerol, 1 mM sodium orthovanadate, 0.5 mM dithiothreitol, 1 mM 
phenylmethylsulfonyl fluoride, 2 μg/ml aprotinin, 2 μg/ml leupeptin, and 2 μg/ml pepstatin. Proteins 
from cell lysates were separated by 10% sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gel 
electrophoresis (Bio-Rad), and transferred to nitrocellulose membranes (Invitrogen). Immunoblots 
were probed with antibodies recognizing: ITK (2F12) and phospho-BTK (Y223) (Cell Signaling).  
Signals were detected with a Li-Cor Odyssey imager. 
 
Isolation of PBMC and NK cells: 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coat (New York Blood 
Center) by Ficoll density gradient centrifugation. Natural killer (NK) cells were isolated by negative 
selection from PBMC according to manufacturer’s protocol (Stemcell Tech). Isolated NK cell purity 
was over 85% as assessed by flow cytometry using anti-CD3 and anti-CD56 monoclonal 
antibodies (BD Biosciences). 
 
PBMC and NK cell co-culture experiments: 
PBMC and NK cells were treated with either DMSO, lenalidomide or ibrutinib for one hour prior to 
stimulation with either 3 μg/ml anti-CD3 (OKT3, eBiosciences) for 72 hours or 3 ng/ml IL-2 (R&D 
Systems) overnight, respectively. Prior to co-culturing with MCL cells, target cells were labeled 
with 200 nM of carboxyfluorescein succinimidyl ester (CFSE, Invitrogen). PBMC or NK cells were 
co-cultured with target cells at a defined ratio for an additional four hours.  Subsequently, 
supernatant was collected for Granzyme B ELISA and apoptosis in labeled target cells was 
determined by flow cytometric analysis of Annexin V (BD Biosciences) and ToPro-3 (Invitrogen) 
according to manufacturer’s protocol.   
See supplemental experimental procedures for additional details. 
 
 
Results:  
NK cells increase relative to total lymphocytes in patients with MCL who respond to 
lenalidomide therapy 
Lenalidomide has demonstrated clinically significant benefits in patients with R/R MCL; however, 
the molecular mechanism in MCL has not been described. In vitro studies have demonstrated 
lenalidomide has a dual MOA in other hematologic malignancies that includes both 
immunomodulatory effects on multiple immune cell types as well as cell autonomous apoptotic 
activity (Davies et al., 2001; Gandhi et al., 2014; Lopez-Girona et al., 2011; Mitsiades, 2002; 
Schafer et al., 2003; Wu et al., 2008). In a post-hoc analysis of biomarker data collected in the 
CC-5013-MCL-002 trial, we sought to examine the immunomodulatory effects of lenalidomide 
using samples collected from patients who had been treated with either lenalidomide or 
investigator’s choice (single agent rituximab, gemcitabine, fludarabine, chlorambucil, or 
cytarabine) (Trněný et al., 2016). Peripheral blood samples were collected at Cycle 1 Day 1 
(C1D1, pre-treatment), Cycle 1 Day 4 (C1D4), Cycle 2 Day 15 (C2D15). Flow cytometric profiling 
of T-cell (CD3 / CD4 / CD8 / CD45RA / CD25 / CD27), B-cell (CD19 / CD20 / CD5 / CD23 / CD40 
/ CD22 / Kappa / Lambda), and NK-cell (CD56 / CD16 / CD3 / CD69) subsets was performed. In 
baseline measurements of B, T and NK cells (total or subset populations), no significant 
differences were observed when comparing non-responder (stable or progressive disease) and 
responder (complete or partial response) outcome sub-groups in either lenalidomide (N=50) or 
investigator’s choice control (N=18) arms (data not shown). However, we detected significantly 
elevated (p≤ 0.05) levels of NK cells, as measured by CD3-CD56+CD16+, relative to total 
lymphocytes in patients who responded to lenalidomide (N=20, black dots) at both C1D4 and 
C2D15. Most importantly, this increase at C1D4 was also significantly different between 
responders compared to non-responders (N=14, gray dots) in the lenalidomide arm (Fig 1A). 
These observations were independent of baseline demographics such as age (71 versus 64), 
number of prior therapies (2 vs 1) and ECOG score (1 vs 1) in responders compared to non-
responders. Additionally, no differences in NK cell levels relative to total lymphocytes were 
observed in either responders or non-responders within the investigator’s choice single agent 
arm. We confirmed our clinical observations with pre-clinical experiments, where treatment with 
lenalidomide increased CD56+CD16+ NK cells in proportion to total lymphocytes in a CD3-
stimulated peripheral blood mononuclear cell (PBMC) in vitro model with flow cytometric analysis 
(data not shown). Importantly, lenalidomide treated patients whose CD56+CD16+ NK cells 
expanded above the median value of 9.8% observed at C1D4 demonstrated a trend towards 
prolonged progression free survival (PFS) (median of 48.7 weeks vs 16.9 weeks, p=0.11) (Fig 
1B). Additionally, there was a trend towards enhanced overall survival (OS) (median of undefined 
vs 86.7 weeks, p=0.08) (Fig 1C). Taken together, these data provide a potential 
pharmacodynamic marker for response to lenalidomide in patients with R/R MCL and suggest 
that a lenalidomide-dependent increase in NK cells may contribute in part to extended PFS and 
OS. 
Clinical response to lenalidomide is not associated with baseline tumor microenvironment 
cereblon expression nor with mutations reported to impact response to ibrutinib  
We investigated the association of cereblon protein levels with clinical response by 
analyzing lymph node biopsies from R/R MCL patients enrolled in MCL-002. As shown in 
representative images in Fig 2A, cereblon was expressed at similar levels in patients with differing 
responses to therapy and quantitative H-scores for cereblon protein levels in total, nuclear, and 
cytoplasmic compartments did not correlate with clinical response to lenalidomide (Fig 2B). 
Previous studies have demonstrated that mutations in epigenetic regulators, mTOR signaling and 
the Bruton’s tyrosine kinase (BTK) pathway, specifically CREBBP, CD79A, ERBB4, MLL2, 
MTOR, PLCG2, and WHSC1 genes negatively correlate with clinical response to ibrutinib in 
MCL.(Balasubramanian et al., 2014; Lenz, 2016) To determine if mutations in these seven genes 
influenced response to lenalidomide, we sequenced 19 patients (7 responders and 12 non-
responders) from the MCL-002 trial using the Foundation One Heme panel. Our analysis 
suggested that lenalidomide retains activity in MCL patients whose tumors contain mutations that 
are associated with ibrutinib resistance, specifically MLL2 where 7 patients achieved clinical 
outcomes of 4 responders and 3 non-responders (Fig 2C).  
 
Lenalidomide increases immune cell-mediated cytotoxicity against MCL cell lines while 
ibrutinib does not 
To further investigate the immunomodulatory effects of lenalidomide we utilized an in vitro co-
culture cytotoxicity assay. CD3-stimulated PBMCs were treated with DMSO or 1 nM to 10 µM 
lenalidomide for 3 days prior to co-culture with CFSE labeled MCL cell lines. Increasing 
concentration of lenalidomide resulted in a 3 to 6.9-fold increase in CD3-stimulated immune cell-
mediated cell death in Jeko-1, Granta-519, and Mino MCL cell lines as measured by Annexin V 
and ToPro-3 staining. Treatment with 10 μΜ lenalidomide was significantly more effective at 
inducing PBMC-mediated apoptosis in all three MCL cell lines as compared to DMSO controls 
(p≤0.05 Jeko-1, p≤0.0001 Granta-519, p≤0.001 Mino) (Fig 3A, left panel). In contrast, treatment 
with 10 nM to 1 µM ibrutinib for 3 days prior to a four-hour co-culture with the same three MCL 
cell lines revealed no significant difference in induction of apoptosis compared to DMSO treated 
PBMCs (Fig 3A, right panel). In addition, analysis of the supernatant from these co-culture assays 
revealed that lenalidomide treatment increased secreted granzyme B levels in a dose dependent 
manner compared to vehicle controls (Fig 3B, left panel); however, treatment with ibrutinib did not 
result in increased granzyme B secretion (Fig 3B, right panel). Together, the functional cytotoxicity 
assays buttress the ability of lenalidomide to potentiate immune-mediated killing of MCL tumor 
cells and reveal granzyme B as a potentially important immunologic marker. 
Given the duality of lenalidomide’s MOA in other disease settings such as MM and DLBCL, 
we next examined the cell autonomous effects of lenalidomide in MCL. We first examined whether 
treatment with lenalidomide (0.01 nM to 10 µM) impacted tumor cell proliferation by screening a 
panel of six MCL cell lines (Granta-519, Jeko-1, Mino, JVM-2, Rec-1, and Z138) for 5 days. 
Surprisingly, treatment with lenalidomide did not result in any significant changes in cellular 
proliferation as measured by 3H-thymidine incorporation (Fig S1A) or apoptosis in any of the MCL 
cell lines tested (Fig S1B). In contrast to lenalidomide, MCL cells treated with ibrutinib (0.01 nM 
to 10 μΜ) or doxorubicin (150 nM to 10 μΜ) for 5 days resulted in decreased proliferation (Fig 
S1C,D). 
 
Lenalidomide enhances NK cell-mediated cytotoxicity and lytic immune synapse 
formation 
To determine whether NK cells were responsible for the ability of lenalidomide to promote 
immune-mediated cytotoxicity against MCL tumor cells, we utilized our in vitro co-culture 
cytotoxicity assay using negatively isolated CD56+ NK cells. Interleukin-2 (IL-2) stimulated NK 
cells treated with 1 nM to 10 µM lenalidomide for 18 hours prior to the co-culture with MCL cells 
resulted in remarkably similar anti-tumor activity to that observed in the previous co-culture assay 
using PBMCs (Fig 4A). Lenalidomide-treated NK cells were significantly more effective at inducing 
NK cell-mediated apoptosis of all three MCL cell lines when compared to vehicle treated cells 
(p≤0.01 Jeko-1, p≤0.01 Granta-519, p≤0.01 Mino) (Fig 4A). In contrast, treatment with 0.5 µM 
ibrutinib resulted in significantly reduced levels of apoptosis as measured by Annexin V/ToPro-3 
staining in all 3 MCL cell lines (p≤0.0001 Jeko-1, p≤0.01 Granta-519, p≤0.0001 Mino) compared 
to vehicle treated NK cells (data not shown). Moreover, supernatants from lenalidomide-treated 
co-cultures of NK cells with MCL cells revealed significantly increased granzyme B levels when 
compared to vehicle controls (p≤0.0001 Jeko-1, p≤0.01 Granta-519) (Fig 4B). Supernatants from 
ibrutinib-treated NK cells revealed significantly decreased levels of granzyme B compared to 
vehicle control treatment (p≤0.0001 Jeko-1 and Granta-519) suggesting that ibrutinib inhibits NK 
cell-mediated cytotoxicity (Fig 4B). The tyrosine kinase IL-2 inducible T cell kinase (ITK), has been 
shown to positively regulate FcγRIII, (also known as CD16) mediated NK cell cytotoxicity and 
ADCC (Khurana, Arneson, Schoon, Dick, & Leibson, 2007). Given the homology between BTK 
and ITK, we explored ibrutinib treatment on ITK activation in CD16 cross-linked NK cells. Ibrutinib 
resulted in decreased phosphorylation at tyrosine 180 (Y180) of ITK, confirming ITK as a known 
target of ibrutinib (Fig 4C) (Dubovsky et al., 2013). These data are consistent with previous reports 
indicating that ibrutinib antagonized rituximab-dependent NK cell-mediated cytotoxicity (Kohrt et 
al., 2014; Rajasekaran et al., 2014; Roit et al., 2014), however one group has demonstrated that 
ibrutinib increased NK cell-mediated activity of mouse NK cells (Kuo et al., 2016). 
The addition of anti-CD20 monoclonal antibodies such as rituximab and obinutuzumab 
(GA101) to standard therapies have significantly improved responses in multiple hematologic 
malignancies (Coiffier  et al., 2002; Goede  et al., 2014). Lenalidomide has been shown to 
enhance ADCC and has demonstrated significant clinical benefit in non-Hodgkin’s lymphoma 
(NHL).(Fowler et al., 2014; Hernandez-Ilizaliturri et al., 2005; Nowakowski et al., 2014; Ruan et 
al., 2015; Wang et al., 2012; Wu et al., 2008; L. Zhang et al., 2009) We sought to investigate the 
effect of lenalidomide in combination with CD20 targeting antibodies in a PBMC co-culture model. 
Expression of CD20 was confirmed via flow cytometry in Z138, JVM-2, and Granta-519 cell lines 
(Fig S2A). CD3 stimulated PBMCs were treated with lenalidomide (0.1 µM or 1 µM) for 3 days 
prior to four-hour co-culture with Granta-519, JVM-2, or Z138 cells that had been labeled with 
rituximab or obinutuzumab. Treatment with lenalidomide enhanced rituximab and obinutuzumab 
ADCC against all three MCL cell lines (Fig 4D, Fig S2B). Interestingly, the combination of 
lenalidomide with obinutuzumab was more potent than the combination with rituximab in all three 
cell lines, resulting in approximately 30% of MCL cells remaining viable following only four hours 
of co-culture.  
Conditional deletion of Aiolos from NK cell lineages has been previously reported to result 
in NK cells that were hyper-reactive against tumor cells.(Holmes et al., 2014) We examined the 
effect of lenalidomide treatment on Aiolos and Ikaros protein expression in CD56+ NK and CD3+ 
T cells following treatment of PBMCs with increasing concentrations of lenalidomide (1 nM to 10 
µM) for 3 days compared to vehicle control. Our results showed that lenalidomide treatment 
decreased Aiolos and Ikaros levels in CD3+ T cells, which is consistent with previous reports (Fig 
4F).(Gandhi et al., 2014; Kronke et al., 2014) We also observed degradation of both Aiolos (40%) 
and Ikaros (95%) after lenalidomide treatment in CD56+ NK cells (Fig S3A) suggesting that 
degradation of Aiolos and Ikaros may increase persistent NK cell activity against tumor cells.  
We hypothesized that lenalidomide treatment could modulate the immunological synapse, 
which is the dynamic signaling interface formed between a NK cell and a target cell. Formation of 
the NK cell immune synapse controls the directed delivery of lytic granule contents for targeted 
cell lysis. F-actin polymerization is a hallmark of the activated NK cell lytic synapse, whereas the 
inhibitory immune synapse observed in NK cells is primarily actin-independent (Orange, 2008). 
Using confocal microscopy, we investigated the effects of lenalidomide on F-actin polymerization 
by visualizing NK:MCL cell conjugate interactions. Treatment of Jeko-1 and CD56+ NK cells for 
24 hours with 1 µM lenalidomide prior to 30 minutes of co-culture resulted in increased F-actin 
polymerization as compared to DMSO control (Fig 4E). This increase in F-actin polymerization 
and focal expression pattern are characteristic of an immune synapse.(Davis & Dustin, 2004) 
Quantification of immune synapse formation in three independent experiments revealed that 
treatment with lenalidomide resulted in a statistically significant increase in immune synapse 
strength as measured by F-actin polymerization at the contact between a NK cell and a Jeko-1 
cell (p≤0.0001). Additionally, significant relocalization of perforin to the immune synapse 
(p≤0.0001), a primary attribute of a functional lytic synapse, was observed (Fig 4F).  
 
Discussion: 
Lenalidomide has significant activity in B-cell malignancies such as MM and NHL including 
DLBCL, FL and MCL.(Benboubker et al., 2014; Leonard et al., 2015; Trněný et al., 2016; Wiernik 
et al., 2008). To date, the mechanistic understanding of lenalidomide’s anti-tumor activity was 
understood to be a combination of both direct cell autonomous and immune-mediated effects. In 
this study, we provide novel evidence that the clinical activity of lenalidomide in MCL is mediated 
through activation of NK cell directed cytotoxicity in patients. A subset analysis of longitudinal 
collected biomarker samples reveals that MCL patients enrolled on the MCL-002 trial who 
responded to lenalidomide had a significant expansion of CD56+CD16+ NK cells relative to total 
lymphocytes compared to non-responders. Notably, this NK cell expansion was measurable as 
early as four days post-treatment initiation. Our correlative studies reveal that those patients 
whose NK cells expanded above the median increase for this population had a trend towards 
prolonged PFS and improved OS compared to patients whose NK cells expansion was below the 
median increase threshold. Interestingly, profiling of T cell subsets revealed a significant increase 
in CD4+CD25+ activated T cells in lenalidomide treated patients at C2D15 compared to C1D1 
(data not shown). However, this effect was not significantly different between responders and 
non-responders to lenalidomide. Further supporting the concept of an immune mediated anti-
tumor process, lenalidomide exhibits activity in patients with a spectrum of lymphoma-associated 
mutations including those that have been correlated with disruption of ibrutinib activity in both 
MCL and CLL (Balasubramanian et al., 2014; Woyach et al., 2014), however these observations 
should be confirmed in a larger cohort. 
 While the precise molecular mechanism of lenalidomide’s enhancement of NK cell activity 
is unknown, we describe a shared mechanism with T cells in that engagement of lenalidomide 
with CRL4CRBN results in decreased levels of the transcription factors Aiolos and Ikaros through 
ubiquitination and subsequent proteasomal degradation. Genetic deletion of Aiolos has been 
reported to significantly enhance NK mediated anti-tumor effects (Holmes et al., 2014). 
Interestingly, lenalidomide treatment of NK cells has been shown to result in enhanced IFN-
gamma secretion and actin remodeling as early as 90 minutes post-treatment, when degradation 
of Aiolos and Ikaros by CRL4CRBN is minimal (Lagrue, Carisey, Morgan, Chopra, & Davis, 2015). 
We hypothesize that the polymerization of F-actin and relocalization of perforin, two 
characteristics of an active immunological synapse, that were observed in our studies may be a 
distinct and independent mechanism from degradation of Aiolos and Ikaros and is currently under 
further investigation.  
In conclusion, we believe these data identify a distinct immune-mediated mechanism of 
action for lenalidomide in MCL that should be confirmed in larger clinical studies. Lenalidomide 
treatment enhanced NK cell-mediated cytotoxicity by promoting lytic immune synapse formation 
and polarized granzyme B release. Furthermore, the improvement of anti-CD20 mediated ADCC 
following lenalidomide treatment provides pre-clinical mechanistic support for the combination of 
lenalidomide with anti-CD20 antibodies in MCL which has shown remarkable clinical activity in 
this disease setting with an overall response rate of 92%, complete response rate of 64% and 
progression free survival at 2 years of 85% (Ruan et al., 2015). 
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Supporting information: 
Materials and Methods 
Fig. S1. Cell autonomous effects of lenalidomide, ibrutinib and doxorubicin in MCL cell lines. 
Fig. S2. Lenalidomide dependent antibody dependent cell-mediated cytotoxicity of Rituximab and 
Obinutuzumab labeled MCL cell lines. 
Fig. S3. Lenalidomide treatment results in decreased levels of Aiolos and Ikaros. 
 
 
Figure Legends: 
Fig. 1. Examination of peripheral NK cells in patients treated with lenalidomide or 
investigators choice in MCL-002. (A) Scatter plot of CD3-CD56+16+ proportions to total 
lymphocytes collected at indicated time points and grouped by responder/non-responder for the 
lenalidomide and investigator’s choice arm. *: p<0.05 (B) Kaplan-Meier curves plotting the 
progression free survival of patients above (red line) or below (black line) the median increase in 
relative proportion of NK cells to lymphocytes. (C) Kaplan-Meier curves plotting the overall 
survival of patients above (red line) or below (black line) the median increase in relative proportion 
of NK cells to lymphocytes. 
 
Fig. 2. Lenalidomide activity in CC-5013-MCL-002 is independent of mutational status and 
cereblon protein levels. (A) Representative fields of cereblon IHC on FFPE lymph node biopsies 
obtained from MCL-002 patients grouped by response to lenalidomide. (B) Total, nuclear and 
cytoplasmic cereblon were scored using an H-score system. Box and whisker plots for H-scores 
grouped by best overall response to lenalidomide. Progressive disease (PD), n=7; stable disease 
(SD), n=17; partial response (PR), n=21. (C) Graphical representation of mutational status for 
CREBBP, CD79A, ERBB4, MLL2, MTOR, PLCG2 and WHSC1 compared to best overall 
response from biopsies (n=19) obtained prior to lenalidomide treatment. 
 
Fig. 3. Lenalidomide and ibrutinib dependent PBMC-mediated cytotoxicity against MCL cell 
lines. (A) CD3 stimulated PBMCs treated with DMSO, lenalidomide (0-10 μM), or ibrutinib (0-1 
μM) for 3 days, prior to a four hour co-culture with MCL cell lines (Granta-519, Jeko-1, and Mino). 
Apoptosis was analyzed by Annexin V and ToPro-3 staining. Data from 3 independent 
experiments are presented as percentage of viable cells versus DMSO control ± standard error 
of the mean (SEM). (B) Supernatant from co-cultures of PBMC and MCL cells were analyzed for 
granzyme B by ELISA. Data are presented as fold change from DMSO ± SEM.  
 
Fig. 4. Lenalidomide dependent NK cell mediated cytotoxicity and immune synapse 
formation (A) IL-2 stimulated NK cells treated with DMSO or lenalidomide (0-10 μM) for 18 hours, 
prior to a four hour co-culture with MCL cell lines (Granta-519, Jeko-1, and Mino). Apoptosis was 
analyzed by Annexin V and ToPro-3 staining. Data from 3 independent experiments are 
presented as percentage of viable cells versus DMSO control ± SEM. (B) Supernatant from co-
cultures of MCL cells and NK cells treated with DMSO, lenalidomide (1 μM) and ibrutinib (500 
nM) were analyzed for granzyme B by ELISA. Data from 3 independent experiments are 
presented as fold change from DMSO ± standard deviation (SD). (C) IL-2 stimulated CD56+ NK 
cells treated with DMSO, lenalidomide or ibrutinib (0.1-1 μM) for 18 hours prior to CD16 
stimulation. Cell lysates were separated by SDS-PAGE, and levels of phosho-ITK (Y180) and ITK 
were assessed. (D) CD3 stimulated PBMCs treated with DMSO, lenalidomide (0.1-1 μM) for 3 
days, prior to a four hour co-culture with rituximab or obinutuzumab labeled Granta-519 cells. 
Apoptosis was analyzed by Annexin V and ToPro-3 staining. Data from 3 independent 
experiments are presented as percentage of viable cells versus DMSO ± SEM. (E) 
Representative fields of immune synapse formation between NK and Jeko-1 cells treated with 
DMSO or lenalidomide (1 μM). F-actin staining via phalloidin incorporation (red) and perforin 
(green), MCL cells were labeled with CMAC (blue). (F) Polymerized F-actin (left panel) and 
perforin (right panel) localized to the immune synapse was quantified. Each data point represents 
a distinct immune synapse. Results of 3 independent experiments are shown. **: p<0.01, ****: 
p<0.0001 
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Supporting information: 
Materials and Methods 
Figure. S1. Cell autonomous effects of lenalidomide, ibrutinib and doxorubicin in MCL cell lines. 
Figure. S2. Lenalidomide dependent antibody dependent cell-mediated cytotoxicity of Rituximab 
and Obinutuzumab labeled MCL cell lines. 
Figure. S3. Lenalidomide treatment results in decreased levels of Aiolos and Ikaros. 
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Supplemental Materials and Methods 
 
Granzyme B ELISA: 
Supernatants harvested from co-culture experiment were examined at 1:5 dilution in complete 
media for secreted Granzyme B analysis according to manufacturer’s protocol (Cell Science). 
 
Flow Cytometry: 
MCL cells (1x105 cells/ml) were treated with either DMSO or various concentrations of 
lenalidomide for 7 days. Cells were collected and apoptosis was analyzed through flow 
cytometric analysis of Annexin V and To-Pro 3 staining according to manufacturer’s protocol 
(Life Technologies). The gating strategy utilized for determining the quadrants in the flow 
cytometry data segregates the majority of viable cells in the DMSO control within each cell line 
as Annexin V negative/ ToPro-3 negative. BDFACS Fortessa flow cytometer equipped with 
FACSDIVA (Becton-Dickinson) were used for acquisition.  Flowjo (Flowjo LLC) was used for 
analysis of exported FACS data. 
 
Proliferation assays 
2x104 cells were plated per well in media containing either DMSO or various concentrations of 
lenalidomide or ibrutinib. Cells were cultured for 5 days at 37 degrees Celsius after which 
tritiated thymidine was added to the cell culture for the final 6 hours. Cells were subsequently 
harvested onto filter plates. After the plates have dried, scintillation fluid was added to the plates 
and read on a Top-count reader (Perkin-Elmer). 
 
Statistical Analysis: 
Significance among different groups were assessed using one-way ANOVA from Graphpad 
Prism (GraphPad Software, Inc.). Data were expressed as mean ± SEM.  In this study, *:  
p<0.05, **:  p<0.01, ***:  p<0.001, **** p<.0001. 
 
Immune Synapse Immunofluorescence: 
Briefly, Jeko-1 MCL cells (2 × 106) were stained with CellTracker Blue CMAC according to 
manufacturer's instructions and pulsed with 2 μg/mL of a cocktail of staphylococcal 
superantigens (sAgs; SEA and SEB; Sigma-Aldrich) for 30 minutes at 37°C. Jeko-1 cells were 
centrifuged at 200g for 5 minutes with an equal number of DMSO or Lenalidomide treated NK 
cells (purified from PBMC as described above) and incubated at 37°C for 15 minutes. Cells 
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were transferred onto microscope slides (Menzel-Glaser Polysine slides; Thermo Scientific) 
using a cell concentrator (Cytofuge 2) and fixed for 15 minutes at room temperature with 3% 
methanol-free formaldehyde (TABB Laboratories) in PBS. Immunofluorescent labeling was 
done using Cytofuge2 cell concentrator units. Cells were permeabilized with 0.3% Triton X-100 
(Sigma-Aldrich) in PBS for 5 minutes and treated for 10 minutes with 0.1% BSA in PBS blocking 
solution. Primary and secondary antibodies were applied sequentially for 45 minutes at 4°C in 
5% goat serum (Sigma-Aldrich) in PBS blocking solution. F-actin was stained with rhodamine 
phalloidin and perforin was stained with (clone dG9, Biolegend) according to manufacturer's 
protocol. After washing, the cell specimens were sealed with 22- × 32-mm coverslips using 
fluorescent mounting medium (Dako). Medial optical section images were captured with a Zeiss 
510 confocal laser-scanning microscope using a 63×/1.40 oil objective and LSM Version 3.2 
SP2 imaging software (Zeiss). Detectors were set to detect an optimal signal below saturation 
limits. Fluorescence was acquired sequentially to prevent passage of fluorescence from other 
channels (Multi-Track). Image sets to be compared were acquired during the same session 
using identical acquisition settings. Blinded confocal images were analyzed using AxioVision 
Version 4.8 image analysis software (Zeiss). NK/Jeko-1 cell conjugates were identified only 
when NK cells were in direct contact interaction with Jeko-1 (blue fluorescent channel). The 
AxioVision area analysis tool was then used to measure the total area (in square micrometers) 
of F-actin (red fluorescent channel) accumulation at all NK-cell contact sites and synapses with 
Jeko-1 cells. These data were then exported into Prism Version 5 software (GraphPad) for 
statistical analysis and to generate a mean area value per experimental population.  
 
Foundation Medicine Mutational Analysis: 
DNA was extracted from formalin-fixed paraffin-embedded (FFPE) using the Maxwell 16 FFPE 
Plus LEV DNA Purification kit (Promega) and quantified using the PicoGreen fluorescence 
assay (Invitrogen). Library construction was performed as previously described using 50–200 ng 
of DNA sheared by sonication to ~100–400 base pairs before end repair, dA addition and 
ligation of indexed Illumina sequencing adaptors. Enrichment of target sequences (3,320 exons 
of 182 cancer-related genes and 37 introns from 14 genes recurrently rearranged in cancer 
representing ~1.1 Mb of the human genome in total) was achieved by solution-based hybrid 
capture with a custom Agilent SureSelect biotinylated RNA baitset. The libraries were 
sequenced on an Illumina HiSeq 2,000 platform using 49 × 49 paired-end reads. Sequence data 
from genomic DNA was mapped to the reference human genome (hg19) using the Burrows-
Wheeler Aligner and were processed using the publicly available SAMtools, Picard and 
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Genome Analysis Toolkit. Genomic rearrangements were detected by clustering chimeric reads 
mapped to targeted introns. 
 
Immunohistochemistry 
Four micron thick FFPE tumor sections were stained with antibodies to cereblon (rabbit 
monoclonal antibody; Celgene CRBN65) using the Bond-Max automated slide strainer (Leica 
Microsystems, Buffalo Grove, IL) and the Bond Polymer Refine Detection Kit.  Antigen retrieval 
was performed with Epitope Retrieval 2 (pH 9.0) for 20 min at 100°C on the instrument.  The 
slides were blocked for endogenous peroxidase activity with Peroxide Block for 5 min at room 
temperature.  Sections were then incubated with primary antibodies for 15 minutes at room 
temperature.  Horseradish peroxidase (HRP) labelled Polymer was applied at the instrument’s 
default conditions and diaminobenzidine tetrahydrochloride (DAB) was used as the enzyme 
substrate to visualize specific antibody localization. Slides were counterstained with 
hematoxylin. H-scores for cereblon were generated with a H Score = Σ(1+i)pi where i is the 
intensity score and pi is the percent of the cells with the corresponding intensity. 
 
CC-5013-MCL-002 clinical study and immunohistochemistry 
The study protocol and informed consent form were approved by the institutional review 
board/independent ethics committees of participating institutions. Written informed consent was 
obtained from all participants, and the trial was conducted in accordance with the Helsinki 
declaration. Immunohistochemistry for cereblon was performed on FFPE samples as described 
above. 
 
 
Supplemental Figure Legends: 
 
Figure S1: Cell autonomous effects of lenalidomide and ibrutinib in MCL cell lines. A) 
MCL cell lines were treated with DMSO or lenalidomide (0.001 nM to 10 μM) for 5 days. 
Proliferation was determined using 3H-thymidine incorporation. Results of three independent 
experiments are shown ± SEM. B) MCL cell lines were treated with DMSO or lenalidomide (0.1-
10 μΜ) for 7 days, after which apoptosis was measured by Annexin V and To-Pro 3 flow 
cytometric analysis. C) MCL cell lines were treated with DMSO or ibrutinib (0.001 nM to 10 μM) 
for 5 days. Proliferation was determined using 3H-thymidine incorporation. Results of three 
independent experiments are shown ± SEM. 
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Figure S2: Lenalidomide dependent antibody dependent cell-mediated cytotoxicity of 
Rituximab and Obinutuzumab labeled MCL cell lines. A) Flow cytometry analysis of CD20 
expression levels on MCL cell lines. Histograms show labeling of CD20 (blue histogram) or with 
a mouse isotype control antibody (red histogram). OCI-LY10 (DLBCL cell line) and NK92 (NK 
cell line) serve as positive and negative controls, respectively. B) Anti-CD3 stimulated PBMCs 
treated with DMSO, lenalidomide (0.1-1 μM) for 3 days, prior to a four hour co-culture with 
Rituximab or Obinutuzumab labeled JVM-2 and Z138 cell lines. Apoptosis was analyzed by 
Annexin V and ToPro-3 staining. Data from 3 independent experiments are presented as 
percentage of viable cells versus DMSO control ± SEM.  
 
Figure S3: Lenalidomide treatment results in decreased levels of Aiolos and Ikaros. (A) 
Flow cytometric analysis of intracellular Aiolos and Ikaros levels in NK and T cells treated with 
DMSO or lenalidomide 0-10 μM). Data from 3 independent experiments are presented as fold 
change from DMSO ± SEM. 
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